perifosine has been researched along with Leukemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baer, MR; Bauer, KS; Carroll, M; Fleckinger, S; Gojo, I; Luger, S; Norsworthy, KJ; Perl, A; Sausville, EA; Tidwell, M | 1 |
| Celeghini, C; Melloni, E; Secchiero, P; Voltan, R; Zauli, G | 1 |
| Celeghini, C; Gattei, V; Rimondi, E; Voltan, R; Zauli, G | 1 |
| Chin, A; Ciancaglini, P; de Oliveira, KT; dos Santos, GA; Faça, VM; Falcão, RP; Ferreira, GA; Greene, LJ; Hanash, SM; Izumi, C; Leopoldino, AM; Rego, EM; Scheucher, PS; Simão, AM; Thomé, CH | 1 |
| Bauer, C; Dai, Y; Dent, P; Grant, S; Payne, SG; Rahmani, M; Reese, E; Spiegel, S | 1 |
1 trial(s) available for perifosine and Leukemia
| Article | Year |
|---|---|
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Treatment Outcome; Young Adult | 2013 |
4 other study(ies) available for perifosine and Leukemia
| Article | Year |
|---|---|
Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Drug Screening Assays, Antitumor; Humans; Imidazoles; Leukemia; Phosphorylcholine; Piperazines; Tumor Cells, Cultured | 2010 |
Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; E2F1 Transcription Factor; Humans; Leukemia; Mutation; Phosphorylcholine; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2011 |
Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line; Cell Proliferation; Cholesterol; Enzyme Activation; Humans; Leukemia; Membrane Microdomains; Oxides; Phosphatidylinositol 3-Kinases; Phospholipids; Phosphorylcholine; Protein Structure, Tertiary; Proteome; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction | 2012 |
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Butyrates; Cell Growth Processes; Cell Line, Tumor; Ceramides; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia; MAP Kinase Signaling System; Mitochondria; Mitogen-Activated Protein Kinase 3; Phosphorylcholine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vorinostat | 2005 |